Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140900 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
A Phase 1 study of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT07140900 is a Phase 1 study of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) that is actively recruiting participants, run by Amgen. The registered enrollment target is 60 participants, below the 71-participant average among 5 other Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials with a reported enrollment target (15% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT07140900, a Phase 1 study of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Conditions Studied
Interventions
- DRUG Darolutamide
- DRUG Abiraterone
- DRUG Xaluritamig
Study Locations (11)
Victoria
- Cabrini Hospital - Clayton
- Peter MacCallum Cancer Centre - Melbourne
- The Alfred Hospital - Melbourne
Other
- Kantonsspital Graubuenden - Chur
- Centre Hospitalier Universitaire Vaudois - Lausanne
- Kantonsspital Sankt Gallen - Sankt Gallen
New South Wales
- Chris OBrien Lifehouse - Camperdown
- Calvary Mater Newcastle Hospital - Waratah
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- University of Minnesota - Minneapolis
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2030-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07140900
The ClinicalTrials.gov registry entry for NCT07140900 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 5 other Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials with a reported enrollment target (15% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) appearing as the primary indexed condition, and to 3 interventions - of which Darolutamide is the first listed.
NCT07140900 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Victoria, Other, New South Wales.
Frequently Asked Questions
What is clinical trial NCT07140900 about?
NCT07140900 is a clinical study titled "Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer". The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
What is the current status of trial NCT07140900?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-07. Estimated completion is 2030-03-30.
What conditions does trial NCT07140900 study?
This clinical trial studies the following conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
What interventions are being tested in trial NCT07140900?
The interventions under investigation include: Darolutamide (DRUG), Abiraterone (DRUG), Xaluritamig (DRUG).
Who is sponsoring clinical trial NCT07140900?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140900 being conducted?
This trial has 11 study locations across Massachusetts, Minnesota, Tennessee, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RECRUITING · Phase 1
-
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
ACTIVE NOT RECRUITING · Early Phase 1
-
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
ACTIVE NOT RECRUITING · Phase 4
-
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.